Enabling the use of embedded and mobile technologies for high-performance computing

In the late 1990s, powerful economic forces led to the adoption of commodity desktop processors in High-Performance Computing(HPC). This transformation has been so effective that the November 2016 TOP500 list is still dominated by x86 architecture. In 2016, the largest commodity market in computing is not PCs or servers, but mobile computing, comprising smartphones andtablets, most of which are built with ARM-based Systems on Chips (SoC). This suggests that once mobile SoCs deliver sufficient performance, mobile SoCs can help reduce the cost of HPC. This thesis addresses this question in detail.We analyze the trend in mobile SoC performance, comparing it with the similar trend in the 1990s. Through development of real system prototypes and their performance analysis we assess the feasibility of building an HPCsystem based on mobile SoCs. Through simulation of the future mobile SoC, we identify the missing features and suggest improvements that would enable theuse of future mobile SoCs in HPC environment. Thus, we present design guidelines for future generations mobile SoCs, and HPC systems built around them, enabling the newclass of cheap supercomputers.A finales de la década de los 90, razones económicas llevaron a la adopción de procesadores de uso general en sistemas de Computación de Altas Prestaciones (HPC). Esta transformación ha sido tan efectiva que la lista TOP500 de noviembre de 2016 sigue aun dominada por la arquitectura x86. En 2016, el mayor mercado de productos básicos en computación no son los ordenadores de sobremesa o los servidores, sino la computación móvil, que incluye teléfonos inteligentes y tabletas, la mayoría de los cuales están construidos con sistemas en chip(SoC) de arquitectura ARM. Esto sugiere que una vez que los SoC móviles ofrezcan un rendimiento suficiente, podrán utilizarse para reducir el costo desistemas HPC. Esta tesis aborda esta cuestión en detalle. Analizamos la tendencia del rendimiento de los SoC para móvil, comparándola con la tendencia similar ocurrida en los añosnoventa. A través del desarrollo de prototipos de sistemas reales y su análisis de rendimiento, evaluamos la factibilidad de construir unsistema HPC basado en SoCs móviles. A través de la simulación de SoCs móviles futuros, identificamos las características que faltan y sugerimos mejoras quepermitirían su uso en entornos HPC. Por lo tanto, presentamos directrices de diseño para futuras generaciones de SoCs móviles y sistemas HPC construidos a sualrededor, para permitir la construcción de una nueva clase de supercomputadores de coste reducido

Preeclamptic Women Have Disrupted Placental microRNA Expression at the Time of Preeclampsia Diagnosis: Meta-Analysis

Introduction: Preeclampsia (PE) is a pregnancy-associated, multi-organ, life-threatening disease that appears after the 20th week of gestation. The aim of this study was to perform a systematic review and meta-analysis to determine whether women with PE have disrupted miRNA expression compared to women who do not have PE.Methods: We conducted a systematic review and meta-analysis of studies that reported miRNAs expression levels in placenta or peripheral blood of pregnant women with vs. without PE. Studies published before October 29, 2021 were identified through PubMed, EMBASE and Web of Science. Two reviewers used predefined forms and protocols to evaluate independently the eligibility of studies based on titles and abstracts and to perform full-text screening, data abstraction and quality assessment. Standardized mean difference (SMD) was used as a measure of effect size.Results: 229 publications were included in the systematic review and 53 in the meta-analysis. The expression levels in placenta were significantly higher in women with PE compared to women without PE for miRNA-16 (SMD = 1.51,95%CI = 0.55-2.46), miRNA-20b (SMD = 0.89, 95%CI = 0.33-1.45), miRNA-23a (SMD = 2.02, 95%CI = 1.25-2.78), miRNA-29b (SMD = 1.37, 95%CI = 0.36-2.37), miRNA-155 (SMD = 2.99, 95%CI = 0.83-5.14) and miRNA-210 (SMD = 1.63, 95%CI = 0.69-2.58), and significantly lower for miRNA-376c (SMD = -4.86, 95%CI = -9.51 to -0.20). An increased level of miRNK-155 expression was found in peripheral blood of women with PE (SMD = 2.06, 95%CI = 0.35-3.76), while the expression level of miRNA-16 was significantly lower in peripheral blood of PE women (SMD = -0.47, 95%CI = -0.91 to -0.03). The functional roles of the presented miRNAs include control of trophoblast proliferation, migration, invasion, apoptosis, differentiation, cellular metabolism and angiogenesis.Conclusion: miRNAs play an important role in the pathophysiology of PE. The identification of differentially expressed miRNAs in maternal blood creates an opportunity to define an easily accessible biomarker of PE

Izveštaj o radu Saveza GIG-a SR Crne Gore

Izveštaj o radu Saveza GIG-a SR Crne Gore

Meta-analysis of circulating cell-free dna’s role in the prognosis of pancreatic cancer

Introduction: The analysis of cell-free DNA (cfDNA) for genetic abnormalities is a promising new approach for the diagnosis and prognosis of pancreatic cancer patients. Insights into the molecular characteristics of pancreatic cancer may provide valuable information, leading to its earlier detection and the development of targeted therapies. Material and Methods: We conducted a systematic review and a meta-analysis of studies that reported cfDNA in pancreatic ductal adenocarcinoma (PDAC). The studies were considered eligible if they included patients with PDAC, if they had blood tests for cfDNA/ctDNA, and if they analyzed the prognostic value of cfDNA/ctDNA for patients’ survival. The studies published before 22 October 2020 were identified through the PubMED, EMBASE, Web of Science and Cochrane Library databases. The assessed outcomes were the overall (OS) and progression-free survival (PFS), expressed as the log hazard ratio (HR) and standard error (SE). The summary of the HR effect size was estimated by pooling the individual trial results using the Review Manager, version 5.3, Cochrane Collaboration. The heterogeneity was assessed using the Cochran Q test and I2 statistic. Results: In total, 48 studies were included in the qualitative review, while 44 were assessed in the quantitative synthesis, with the total number of patients included being 3524. Overall negative impacts of cfDNA and KRAS mutations on OS and PFS in PDAC (HR = 2.42, 95% CI: 1.95–2.99 and HR = 2.46, 95% CI: 2.01–3.00, respectively) were found. The subgroup analysis of the locally advanced and metastatic disease presented similar results (HR = 2.51, 95% CI: 1.90–3.31). In the studies assessing the pre-treatment presence of KRAS, there was a moderate to high degree of heterogeneity (I2 = 87% and I2 = 48%, for OS and PFS, respectively), which was remarkably decreased in the analysis of the studies measuring post-treatment KRAS (I2 = 24% and I2 = 0%, for OS and PFS, respectively). The patients who were KRAS positive before but KRAS negative after treatment had a better prognosis than the persistently KRAS-positive patients (HR = 5.30, 95% CI: 1.02–27.63). Conclusion: The assessment of KRAS mutation by liquid biopsy can be considered as an additional tool for the estimation of the disease course and outcome in PDAC patients